{"product_id":"gsk-bcg-matrix","title":"(GSK) GSK plc BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis GSK plc BCG Matrix helps you understand how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArexvy, first RSV vaccine, £1bn-class sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArexvy is a Star in GSK plc’s BCG Matrix: it was first to market in RSV and kept a leading share as uptake in older adults remains early. GSK said Arexvy generated about £1.2bn in 2024 sales, showing £1bn-class demand in a fast-growing category. That growth still needs heavy promotion, since adult RSV vaccination is not yet routine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDovato, leading 2-drug HIV regimen, £2bn-class sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDovato is GSK plc’s leading 2-drug HIV regimen and a clear Star in the BCG matrix. In 2025, it stayed in the £2bn sales class, helped by steady switching from older triple-therapy regimens and broad guideline support. Its strong share in the HIV market shows durable demand and keeps it one of GSK’s best growth engines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCabenuva, long-acting HIV injectable, rapid uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCabenuva remains a Star for GSK plc: the long-acting HIV injectable is still growing fast, and ViiV helped create the category. GSK reported 2025 ViiV sales growth driven by demand for Cabenuva, while the launch still needs heavy patient finding, promotion, and payer access work. Its value comes from a niche with clear uptake, not mature share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNucala, severe eosinophilic disease, expanding indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNucala is a Star in GSK plc’s BCG mix: it serves a fast-growing severe eosinophilic disease niche and keeps extending beyond asthma. GSK won a U.S. COPD approval in 2024, widening the addressable market.\u003c\/p\u003e\n\u003cp\u003eThe product’s scale supports the case: Nucala brought in about £1.7bn in 2024 sales, showing strong asthma-led biologics demand and good pricing power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore indications, more patients, higher growth.\u003c\/li\u003e\n\u003cli\u003eAsthma remains the core revenue base.\u003c\/li\u003e\n\u003cli\u003eCOPD adds a new specialty lane.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eJemperli, oncology label expansion, late-growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJemperli has moved beyond a niche role: its endometrial cancer use broadened the addressable market, and that helped push it into late-growth territory in GSK plc’s BCG mix. In 2024, GSK said Jemperli sales rose sharply, driven by the dMMR\/MSI-H endometrial cancer label and broader uptake. \u003c\/p\u003e\n\u003cp\u003eThat said, it still competes in a crowded immuno-oncology field, so GSK has to keep funding data, access, and sales support. One label win can lift growth fast, but share gains in oncology rarely hold without steady investment. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLabel expansion widened use\u003c\/li\u003e\n\u003cli\u003eEndometrial cancer drove growth\u003c\/li\u003e\n\u003cli\u003eCompetition keeps pressure high\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGSK Stars: Arexvy, Dovato and Nucala Drive Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGSK plc’s Stars are led by Arexvy, Dovato, Cabenuva, Nucala, and Jemperli: each has fast growth, strong share, and ongoing launch spend. Arexvy brought in about £1.2bn in 2024, Nucala about £1.7bn, and Dovato stayed in the £2bn sales class in 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2025\/2024 sales\u003c\/th\u003e\n\u003cth\u003eStar driver\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eArexvy\u003c\/td\u003e\n\u003ctd\u003e£1.2bn\u003c\/td\u003e\n\u003ctd\u003eRSV lead\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDovato\u003c\/td\u003e\n\u003ctd\u003e£2bn class\u003c\/td\u003e\n\u003ctd\u003eHIV switch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNucala\u003c\/td\u003e\n\u003ctd\u003e£1.7bn\u003c\/td\u003e\n\u003ctd\u003eBiologic growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eGSK plc BCG Matrix maps vaccines and specialty drugs as Cash Cows\/Stars, while older products face pressure as Dogs or Question Marks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page GSK plc BCG Matrix easing portfolio prioritization and strategic decision-making\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise source trail for GSK plc, helping verify assumptions fast and strengthening confidence in the analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShingrix, £3bn+ annual sales, dominant shingles vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShingrix is one of GSK plc’s biggest cash cows, with 2024 sales of $3.4bn, or well above £3bn at recent exchange rates. It leads the mature shingles vaccine market and keeps a very high share, so pricing power and margins stay strong. Growth is slower than newer launches, but the brand still throws off a lot of cash for R\u0026amp;D and pipeline bets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrelegy Ellipta, £3bn+ annual sales, mature respiratory franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrelegy Ellipta is a scale respiratory franchise with annual sales above £3bn, making it one of GSK plc’s biggest cash generators. COPD and asthma are mature markets, so demand is broad but growth is steadier than launch-stage drugs. With strong global share in a large patient pool, Trelegy fits the Cash Cow bucket.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTivicay, £2bn+ annual sales, HIV base brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTivicay is GSK plc’s long-established HIV anchor brand and still brings in £2bn+ a year, even as newer long-acting regimens grow faster. Its market is mature, so it is not a high-growth driver, but it remains a strong cash cow that supports profit and funding for the wider HIV portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBexsero, meningitis B leader, steady demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBexsero sits in a mature MenB market with steady repeat use in infant and adolescent schedules across many countries, so demand is recurring rather than cyclical. GSK’s vaccine engine is large: 2025 group sales were about £31bn, and Bexsero’s strong brand keeps it in a high-share, low-growth cash cow slot.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstablished schedule use\u003c\/li\u003e\n\u003cli\u003eStrong brand recall\u003c\/li\u003e\n\u003cli\u003eRecurring, stable demand\u003c\/li\u003e\n\u003cli\u003eFits cash cow profile\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEngerix-B, global hepatitis B staple, mature vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEngerix-B is a mature, global hepatitis B vaccine with steady demand, driven by WHO-backed newborn and adult immunization programs. The brand needs little promotion and fits a cash-cow profile: high operating leverage, low growth, and recurring public-health sales.\u003c\/p\u003e\n\u003cp\u003eWHO estimates 254 million people lived with chronic hepatitis B in 2022, so the core market stays large, but it is mature and price-sensitive. For GSK plc, Engerix-B helps fund newer assets while adding limited upside beyond stable volumes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable demand, low marketing spend\u003c\/li\u003e\n\u003cli\u003eGlobal public-health use supports sales\u003c\/li\u003e\n\u003cli\u003eCash generation exceeds growth potential\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGSK’s Cash Cows Keep the Revenue Engine Running\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGSK plc’s cash cows are mature, high-share brands that still generate large, reliable cash. In 2025, group sales were about £31bn, and Shingrix, Trelegy Ellipta, Tivicay and Bexsero all kept strong, recurring demand in low-growth markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003e2025 sales\u003c\/th\u003e\n\u003cth\u003eWhy cash cow\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eShingrix\u003c\/td\u003e\n\u003ctd\u003e$3.4bn\u003c\/td\u003e\n\u003ctd\u003eLeading shingles vaccine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrelegy Ellipta\u003c\/td\u003e\n\u003ctd\u003e£3bn+\u003c\/td\u003e\n\u003ctd\u003eLarge mature COPD\/asthma base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTivicay\u003c\/td\u003e\n\u003ctd\u003e£2bn+\u003c\/td\u003e\n\u003ctd\u003eEstablished HIV anchor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBexsero\u003c\/td\u003e\n\u003ctd\u003eRecurring\u003c\/td\u003e\n\u003ctd\u003eStable MenB schedule demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eGSK plc Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe GSK plc BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo content or placeholder pages—just the complete, ready-to-use report. Download it instantly and use it for analysis, presentations, or strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvair Diskus, legacy respiratory brand, generic pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdvair Diskus is a legacy respiratory brand in GSK plc’s portfolio, and it fits the Dogs box because long-running generic pressure has eroded its growth profile. The product still adds cash and remains commercially relevant, but the mature market and cheaper substitutes mean it no longer acts as a growth engine. In GSK plc’s BCG mix, this is a defense-and-harvest asset, not a scale-up story.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSeretide, older inhaled therapy, slow growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSeretide is an older inhaled therapy in a slow-growth market, so it fits the Dogs side of GSK plc’s BCG Matrix. Generic and branded rivals have cut its strategic weight, and demand now comes mainly from legacy users rather than new growth. In GSK’s 2025 reporting, this kind of mature franchise carries limited expansion upside and faces continued price pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFlixotide, off-patent inhaled corticosteroid\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFlixotide, GSK plc’s off-patent fluticasone propionate inhaled corticosteroid, sits in a low-growth segment where generics and local brands keep pricing under pressure. It is a well-known, mature product, but the upside is limited because demand growth is weak and switching costs are low. In BCG terms, that makes it a clear Dog: stable cash flow, but little room for expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVentolin, commoditized rescue inhaler, price pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVentolin is a mature rescue inhaler with broad, steady demand, but its market is heavily commoditized and price pressure stays high. Generic salbutamol\/albuterol alternatives cap pricing power, so share gains are limited and growth depends more on volume defense than expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSteady demand, weak pricing power\u003c\/li\u003e\n\u003cli\u003eMature category, low growth upside\u003c\/li\u003e\n\u003cli\u003eGeneric rivalry keeps margins tight\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAugmentin, mature antibiotic, weak growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAugmentin is a mature GSK antibiotic brand, so growth is weak and the cash it earns is limited by heavy generic pressure. In antibiotics, price competition is intense and many products are commoditized, which keeps returns modest versus the capital needed to keep the franchise in market. This fits a Dogs profile: low growth, low strategic upside, and little room for margin expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOld brand, weak growth\u003c\/li\u003e\n\u003cli\u003eGeneric competition दब?\u003c\/li\u003e\n\u003cli\u003eModest returns on capital\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGSK’s Legacy Brands: Cash-Generating Dogs Under Generic Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAdvair Diskus, Seretide, Flixotide, Ventolin, and Augmentin fit Dogs in GSK plc’s BCG Matrix because each is mature, off-patent, and under heavy generic price pressure. They still generate cash, but 2025 demand is mostly legacy, with little growth or margin upside. GSK plc’s role here is to harvest cash, not expand share.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eBCG\u003c\/th\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvair\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003ctd\u003eGenerics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVentolin\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003ctd\u003eCommoditized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBlenrep, myeloma relaunch bet, uncertain traction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBlenrep targets multiple myeloma, a market with about 35,000 new U.S. cases a year, so the upside is real. But after its 2022 withdrawal, GSK still has to prove lasting demand and cleaner execution. With DREAMM-7 and DREAMM-8 supporting relaunch, it is a high-potential bet, but traction is still not locked in.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDepemokimab, late-stage asthma asset, low current share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDepemokimab is still pre-launch, so its current share is effectively 0, even though it targets biologic-treated asthma and eosinophilic diseases. GSK’s phase 3 data support the asset, but it still needs regulatory approval and launch spend before it can win share. Its twice-yearly dosing could help it stand out if GSK converts the promise into prescriptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBepirovirsen, chronic hepatitis B program, big upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChronic hepatitis B affects about 254 million people worldwide and causes roughly 1.1 million deaths a year, so the unmet need is huge. \u003c\/p\u003e\n\u003cp\u003eBepirovirsen is GSK plc’s best shot at a functional cure in this area, and even modest HBsAg loss rates in late-stage data could open a large high-value market if approval follows. \u003c\/p\u003e\n\u003cp\u003eUntil phase 3 results and regulators confirm benefit, it stays a classic question mark in the BCG Matrix. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGepotidacin, new antibiotic launch, near-zero share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGepotidacin is a question mark for GSK plc: its share is effectively zero before launch, but FDA approved Blujepa on 25 Mar 2025 for uncomplicated UTI in females 12+, opening a new market. As a first-in-class antibiotic, it can scale fast if resistance stays high and access is broad. Still, stewardship rules may cap volume and slow share gains.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNear-zero share pre-launch\u003c\/li\u003e\n\u003cli\u003eFDA approval: 25 Mar 2025\u003c\/li\u003e\n\u003cli\u003eFirst-in-class, high upside\u003c\/li\u003e\n\u003cli\u003eStewardship may limit uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSo the bet is adoption, not brand power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCureVac mRNA flu vaccine, platform play, pre-commercial\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCureVac’s mRNA flu program is a classic \"question mark\" for GSK plc: the seasonal flu market is large, but the asset is still pre-commercial and needs heavy spend on late-stage trials, manufacturing, and launch work. mRNA keeps GSK in a fast-moving platform, but it has not yet proven it can beat entrenched flu vaccine players.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBig market, no sales yet\u003c\/li\u003e\n\u003cli\u003emRNA platform adds upside\u003c\/li\u003e\n\u003cli\u003eHigh cash need before launch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGSK’s Hidden Upside: Four Late-Stage Assets, One Approved\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGSK plc’s question marks are mostly late-stage assets with near-zero share but clear upside. Blenrep, depemokimab, bepirovirsen, and gepotidacin each target large unmet needs, yet each still depends on approval, uptake, and pricing. Gepotidacin already has FDA approval, while the others still need proof that trials can turn into sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eUpside\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBlenrep\u003c\/td\u003e\n\u003ctd\u003eRelaunch\u003c\/td\u003e\n\u003ctd\u003eMultiple myeloma\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDepemokimab\u003c\/td\u003e\n\u003ctd\u003ePre-launch\u003c\/td\u003e\n\u003ctd\u003eTwice-yearly dosing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBepirovirsen\u003c\/td\u003e\n\u003ctd\u003ePhase 3\u003c\/td\u003e\n\u003ctd\u003eHBV cure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGepotidacin\u003c\/td\u003e\n\u003ctd\u003eFDA approved\u003c\/td\u003e\n\u003ctd\u003euUTI launch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234451398921,"sku":"gsk-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/gsk-bcg-matrix.webp?v=1785720429","url":"https:\/\/dcfanalyst.com\/products\/gsk-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}